These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35086949)

  • 21. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
    Narayan P; Wahby S; Gao JJ; Amiri-Kordestani L; Ibrahim A; Bloomquist E; Tang S; Xu Y; Liu J; Fu W; Song P; King-Kallimanis BL; Hou S; Gong Y; Kalavar S; Ghosh S; Philip R; Goldberg KB; Theoret MR; Blumenthal GM; Kluetz PG; Sridhara R; Pazdur R; Beaver JA
    Clin Cancer Res; 2020 May; 26(10):2284-2289. PubMed ID: 32001481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
    Barroso-Sousa R; Tolaney SM
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.
    Wood SJ; Gao Y; Lee JH; Chen J; Wang Q; Meisel JL; Li X
    Breast Cancer Res Treat; 2024 May; 205(1):193-199. PubMed ID: 38286889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
    Wang H; Ma H; Sové RJ; Emens LA; Popel AS
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
    Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
    Slater H
    Oncology (Williston Park); 2020 Dec; 34(12):547. PubMed ID: 33395495
    [No Abstract]   [Full Text] [Related]  

  • 28. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
    Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
    JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
    Li J; Yu K; Pang D; Wang C; Jiang J; Yang S; Liu Y; Fu P; Sheng Y; Zhang G; Cao Y; He Q; Cui S; Wang X; Ren G; Li X; Yu S; Liu P; Qu X; Tang J; Wang O; Fan Z; Jiang G; Zhang J; Wang J; Zhang H; Wang S; Zhang J; Jin F; Rao N; Ma B; He P; Xu B; Zhuang Z; Wang J; Sun Q; Guo X; Mo M; Shao Z;
    J Clin Oncol; 2020 Jun; 38(16):1774-1784. PubMed ID: 32275467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Lahdenperä O; Kosonen S; Villman K; Nyandoto P; Nilsson G; Poikonen-Saksela P; Kataja V; Junnila J; Bono P; Lindman H
    JAMA Oncol; 2017 Jun; 3(6):793-800. PubMed ID: 28253390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report.
    Otani Y; Mori K; Morikawa N; Mizutani M; Yasojima H; Masuyama M; Mano M; Masuda N
    Immunotherapy; 2021 Feb; 13(3):189-194. PubMed ID: 33225795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer.
    Page DB; Pucilowska J; Chun B; Kim I; Sanchez K; Moxon N; Mellinger S; Wu Y; Koguchi Y; Conrad V; Redmond WL; Martel M; Sun Z; Campbell MB; Conlin A; Acheson A; Basho R; McAndrew P; El-Masry M; Park D; Bennetts L; Seitz RS; Nielsen TJ; McGregor K; Rajamanickam V; Bernard B; Urba WJ; McArthur HL
    NPJ Breast Cancer; 2023 Jun; 9(1):53. PubMed ID: 37344474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer.
    Foldi J; Blenman KRM; Marczyk M; Gunasekharan V; Polanska A; Gee R; Davis M; Kahn AM; Silber A; Pusztai L
    Breast Cancer Res Treat; 2024 Nov; 208(2):369-377. PubMed ID: 39002068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
    Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
    Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.
    Philipovskiy A; Chambers K; Konstantinidis I; McCallum R; Corral J; Gaur S
    Immunotherapy; 2020 Dec; 12(18):1293-1302. PubMed ID: 32988260
    [No Abstract]   [Full Text] [Related]  

  • 37. Atezolizumab for the treatment of breast cancer.
    Reddy SM; Carroll E; Nanda R
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):151-158. PubMed ID: 32067545
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.
    Cowherd S; Miller LD; Melin SA; Akman S; Isom S; Cole J; Pullikuth A; Lawrence JA
    Cancer Biol Ther; 2015; 16(5):678-83. PubMed ID: 25928118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.
    Rugo HS; Roche H; Thomas E; Chung HC; Lerzo GL; Vasyutin I; Patel A; Vahdat L
    Clin Breast Cancer; 2018 Dec; 18(6):489-497. PubMed ID: 30153978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.